Osmotica Pharmaceuticals (NASDAQ: OSMT) shares have plummeted premarket Thursday in reaction to the announcement of the pricing of its public offering of 14 million shares and warrants to purchase up to 14 million shares.Â
They have been priced at $2.50 per share and accompanying warrant, with the warrants having an exercise price of $3.10 per share. They are immediately exercisable and will expire three and one-half years from the date of issuance.
In addition, the company has granted the underwriter a 30-day option to purchase up to additional 2.1 million shares and/or additional warrants to purchase up to 2.1 million ordinary shares at the public offering price per share and per warrant.
Osmotica, which is a biopharmaceutical company focused on products that target markets with underserved patient populations, said it expects the proceeds to be approximately $35 million. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
This offering is expected to close on or about October 12.
The news has seen Osmotica Pharmaceuticals shares fall 40.52% premarket to $1.82. Its stock price is down over 25% for the year-to-date
Should You Invest in Osmotica Pharmaceuticals Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now